Fig. 3: Outcomes in all patients.
From: FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Overall survival, relapse-free survival and molecular event-free survival from day of starting therapy.
Fig. 3: Outcomes in all patients. | Leukemia
